Autor(es)Johnson Barbara W, Goodman Christin H, Holloway Kimberly, de Salazar P Martinez, Valadere Anne M, Drebot Mike

ResumoCommercial chikungunya virus (CHIKV)-specific IgM detection kits were evaluated at the Centers for Disease Control - Prevention (CDC), the Public Health Agency of Canada National Microbiology Laboratory, - the Caribbean Public Health Agency (CARPHA). The Euroimmun Anti-CHIKV IgM ELISA kit had ? 95% concordance with all three reference laboratory results. The limit of detection for low CHIK IgM+ samples, as measured by serial dilution of seven sera up to 1:12,800 ranged from 1:800 to 1:3,200. The Euroimmun IIFT kit evaluated at CDC - CARPHA performed well, but required more retesting of equivocal results. The InBios CHIKjj Detect MAC-ELISA had 100% - 98% concordance with CDC - CARPHA results, respectively, - had equal sensitivity to the CDC MAC-ELISA to 1:12,800 dilution in serially diluted samples. The Abcam Anti-CHIKV IgM ELISA initially had high performance at CDC - CARPHA, but at CDC, performance was inconsistent between lots. After replacement of the biotinylated IgM antibody controls with serum containing CHIKV-specific IgM - additional quality assurance/control measures, the Abcam kit was rereleased - reevaluated at CDC. The reformatted Abcam kit had 97% concordance with CDC results - limit of detection of 1:800 to 1:3,200. Two rapid tests - three other CHIKV MAC-ELISAs evaluated at CDC had low sensitivity, as the CDC CHIKV IgM in-house positive controls were below the level of detection. In conclusion, laboratories have options for CHIKV serological diagnosis using validated commercial kits.

ImprentaThe American Journal of Tropical Medicine and Hygiene, v. 95, n. 1, p. 182-192, 2016

DescritoresChikungunya virus - Viral infections ; Chikungunya virus - Serological diagnosis ; Chikungunya Virus - Virus ; Chikungunya virus - Public health

Data de Publicação:2016